Melanoma Drug Pipeline: TIL, LAG-3 & TME — PatSnap Eureka
Beyond Checkpoint & BRAF: TIL Therapy, LAG-3, and Tumor Microenvironment Approaches in Melanoma
Approximately half of advanced melanoma patients fail to achieve durable benefit from established PD-1/CTLA-4 and BRAF/MEK regimens. This intelligence report maps the next-generation modalities—TIL adoptive cell therapy, LAG-3 antagonism, TAM targeting, and TME remodeling—emerging from patent filings and academic literature.
Next-Generation Modality Readiness
Clinical maturity of six beyond-checkpoint/BRAF approaches in the retrieved dataset
Why Standard-of-Care Melanoma Therapy Leaves a Critical Unmet Need
Advanced melanoma is defined by high somatic mutational burden and constitutive MAPK pathway activation—predominantly BRAF V600E/K in approximately 50% of cutaneous cases. According to research from the University of Illinois at Chicago, melanomas exhibit among the highest somatic mutation rates of all cancers, creating a strong rationale for immunological targeting strategies beyond PD-1 and CTLA-4.
The central unresolved clinical problem is resistance: approximately half of advanced patients fail to achieve durable benefit from either BRAF/MEK inhibitors or PD-1/CTLA-4 checkpoint blockade. This creates the demand for next-generation modalities—TIL therapy, LAG-3 antagonism, TAM targeting, and broader tumor microenvironment remodeling strategies—that are increasingly visible in both patent filings and the academic literature.
Beyond canonical BRAF, the dataset highlights NRAS mutations (in a non-overlapping subset), KIT alterations (particularly relevant in acral and mucosal melanomas), and CDK4/6 amplification as druggable secondary targets. The tumor microenvironment harbors immunosuppressive cellular populations including tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and regulatory T cells—each representing distinct intervention points.
Novel checkpoints are also emerging. VISTA (V-domain Immunoglobulin Suppressor of T cell Activation) is identified as potentially important in determining invasive potential and treatment response. The CXCR4–CXCL12 chemokine axis is highlighted as a metastasis-promoting pathway, particularly relevant to hepatic spread, while PAR-1 (Protease Activated Receptor-1) is linked to adhesion, invasion, and angiogenesis in metastatic melanoma.
Six Next-Generation Approaches Shaping the Melanoma Pipeline
From clinically validated TIL therapy to preclinical epigenetic targeting, each modality addresses a distinct dimension of checkpoint and BRAF resistance.
TIL Adoptive Cell Therapy
TIL therapy involves ex vivo expansion of autologous tumor-infiltrating lymphocytes from resected tumor material, followed by reinfusion after lymphodepleting conditioning. The Netherlands Cancer Institute describes the approach as producing "robust, reproducible clinical responses" across multiple specialized centers globally. Discussion of lymphodepleting regimens, IL-2 co-administration, and selective TIL fraction expansion signals an established clinical modality with ongoing optimization. The NCI Surgery Branch describes TIL as "an effective treatment for some patients with advanced cancer." No patent filings covering TIL manufacturing were retrieved—competitive differentiation will emerge at the level of manufacturing know-how and combination protocols with checkpoint blockade.
Netherlands Cancer Institute · NCI Surgery BranchLAG-3 Antagonism (Anti-LAG-3 + Anti-PD-1)
LAG-3 (Lymphocyte-Activation Gene 3) is the most prominent novel checkpoint target in the retrieved dataset by patent activity. Bristol-Myers Squibb holds at least three jurisdiction-distinct filings (SG, IL) claiming methods of treating previously untreated metastatic or unresectable melanoma using a CDR-defined anti-LAG-3 antibody combined with anti-PD-1. Biomarker-guided patient selection integrates LAG-3 expression on TILs, PD-L1 on tumor cells, and BRAF V600 mutation status. The mechanistic rationale is dual blockade of LAG-3 and PD-1 to produce additive or synergistic T cell reinvigoration within the TME. Academic literature from Nanjing University of Science and Technology also references LAG-3 in the context of nano-immunomodulator strategies.
Bristol-Myers Squibb · 3 Patent FilingsTME Remodeling: TAM & CAF Targeting
King's College London, Guy's Hospital describes tumor-associated macrophages (TAMs) as a "highly diverse and plastic" cellular subset supporting melanoma growth, angiogenesis, and invasion, outlining monoclonal antibody strategies to redirect TAM polarization or deplete pro-tumor TAM populations as a complement to existing checkpoint immunotherapy. Separately, Chongqing Medical University identifies a six-gene panel of cancer-associated fibroblast (CAF)-related genes predictive of anti-PD-1 therapy response, characterizing CAFs as a majority stromal component of the TME. Both represent academic literature only; no commercial patents covering TAM- or CAF-targeted approaches in melanoma were retrieved—a potential first-mover IP opportunity.
King's College London · Chongqing Medical UniversityOncolytic Virotherapy & Intralesional Therapy
Cleveland Clinic's Taussig Cancer Institute describes intralesional/intratumoral therapies—including oncolytic viruses such as talimogene laherparepvec (T-VEC)—as a strategy to kill tumor cells directly or increase tumor immunogenicity. T-VEC is described as the first FDA-approved intralesional therapy, with ongoing clinical trials combining T-VEC with checkpoint inhibitors including ipilimumab and pembrolizumab. This represents the most clearly clinically validated "beyond checkpoint" modality in this dataset alongside TIL therapy. According to the FDA, T-VEC's approval established a new category of intratumoral immunotherapy.
Cleveland Clinic Taussig Cancer Institute · FDA-ApprovedSmall Molecule Epigenetic & Novel Kinase Inhibitors
The University of Alabama at Birmingham reports that TP-472, a bromodomain-7/9 (BRD7/9) inhibitor, suppresses melanoma tumor growth by blocking ECM-mediated oncogenic signaling and inducing apoptosis in preclinical models. It was identified as the strongest inhibitor of melanoma growth in an unbiased screen of 32 epigenetic inhibitors. Yale University School of Medicine identifies ALK inhibition (ceritinib) as a strategy to overcome BRAFi-acquired resistance mediated through the PI3K/AKT pathway. Cabozantinib (multi-RTK inhibitor) is reported effective in melanoma brain metastasis cell lines by the University of Bergen.
UAB · Yale · University of BergenNano-Based Immunomodulatory Delivery Systems
Nanjing University of Science and Technology describes emerging nano-strategies designed to overcome checkpoint blockade resistance by enhancing tumor cell phagocytosis through checkpoint-mediated internalization or by delivering combination immunomodulators, referencing CTLA-4, PD-1/PD-L1, and LAG-3 as combined targets in a single delivery vehicle. This approach may offer future clinical translation potential, particularly to overcome acquired resistance. Evidence is academic and preclinical only in this dataset. The NIH National Cancer Institute has highlighted nano-delivery as an emerging area in immuno-oncology.
Nanjing University of Science and Technology · 2023Patent Activity & Target Landscape: Quantified Signals
Visual analysis of commercial IP concentration, development stage distribution, and combination therapy evidence across the next-generation melanoma pipeline.
LAG-3 + PD-1 Patent Assignee Concentration in Melanoma
Commercial IP for LAG-3 combination therapy is entirely concentrated in Bristol-Myers Squibb across the retrieved dataset, with academic institutions generating exploratory mechanistic work but zero commercial filings.
Combination Approach Evidence Strength by Modality
Relative evidence density (patent + literature signals) for six combination strategies identified in the retrieved dataset, from clinically validated to early-stage preclinical.
Who Is Driving Innovation in the Melanoma Pipeline?
Commercial IP is concentrated in a single assignee; academic institutions dominate the mechanistic and translational evidence base for next-generation approaches.
Track Competitor IP Activity in Real Time
Monitor Bristol-Myers Squibb LAG-3 filings and emerging academic-to-commercial IP transitions with PatSnap Eureka alerts.
What the Innovation Landscape Means for Drug Developers & Investors
Five evidence-based strategic signals derived from the patent and literature dataset for teams working in the next-generation melanoma space.
LAG-3: Most Commercially Consolidated Next Checkpoint
Bristol-Myers Squibb has filed across multiple jurisdictions for the anti-LAG-3 + anti-PD-1 combination in first-line melanoma, establishing a dominant IP position. Organizations seeking to enter this space will need to design around existing CDR-defined antibody claims or develop alternative LAG-3 binders.
TIL Therapy: Autologous, Non-IP-Intensive Competitive Niche
Clinical evidence in the dataset is reproducible across multiple centers. Competitive differentiation will likely emerge at the level of manufacturing optimization, selective TIL fraction expansion, and combination protocols with checkpoint blockade—areas where IP and process know-how are interdependent.
TME Targets: Academically Rich, Commercially Underdeveloped
The gap between academic mechanistic evidence (King's College London, Chongqing Medical University) and commercial patent filings for TAM-directed antibody or CAF-modulating approaches represents a potential opportunity for first-mover IP capture.
Resistance Biology Is Driving All Combination Design
Retrieved results consistently cite approximately 50% primary or acquired resistance to both checkpoint and BRAF-targeted therapy. Every emerging modality is positioned as a resistance-circumvention strategy. Drug developers should frame clinical and regulatory strategy around post-checkpoint-failure or combination-with-checkpoint positioning.
Convergent Combination Approaches Emerging from the Dataset
Anti-LAG-3 + Anti-PD-1 is the most heavily patent-protected combination in this dataset. Bristol-Myers Squibb filings describe dual antagonism of LAG-3 and PD-1 as a first-line strategy for unresectable melanoma, with optional biomarker stratification by LAG-3 TIL expression, PD-L1 tumor expression, and BRAF V600 mutation status. This may represent the most commercially advanced "beyond checkpoint" approach in the retrieved data.
TIL + Checkpoint Inhibition: The Netherlands Cancer Institute notes that "even in the era of targeted therapy and immune checkpoint inhibition, TIL therapy can be an additional and clinically relevant treatment line," implying sequential or combination use. The integration of TIL with checkpoint blockade is described as an area of future potential.
BRAF/MEK + Checkpoint Blockade (Triple Combination): A systematic review and meta-analysis analyzed five randomized controlled trials evaluating triple combination of anti-PD-1/PD-L1 + BRAF + MEK inhibitors in stage III–IV melanoma. A mathematical modeling paper from Renmin University of China predicts that BRAF/MEK + PD-1 inhibition combination will improve overall survival over either monotherapy. The American Society of Clinical Oncology has highlighted triple combination strategies as a key area of investigation in advanced melanoma.
TAM Reprogramming + Existing Immunotherapy: King's College London signals combining TAM-directed monoclonal antibodies with existing PD-1/CTLA-4 regimens as a strategy for patients currently non-responsive to checkpoint blockade. Epigenetic Priming + Immunotherapy: The BRD7/9 inhibitor TP-472 study signals a potential avenue for combining epigenetic agents with immunotherapy, given the roles of BRD proteins in regulating immune evasion and oncogenic signaling. Explore the full IP analytics platform to track combination patent activity in real time, or review customer case studies from life sciences teams using PatSnap for pipeline intelligence.
Melanoma Drug Pipeline Beyond Checkpoint and BRAF — Key Questions Answered
TIL therapy involves the ex vivo expansion of autologous tumor-infiltrating lymphocytes from resected tumor material followed by reinfusion after lymphodepleting conditioning. The Netherlands Cancer Institute describes the approach as producing robust, reproducible clinical responses across multiple specialized centers globally. Development stage signals suggest an established clinical modality with ongoing optimization rather than early discovery.
Bristol-Myers Squibb Company is the only pharmaceutical company with filed patents in the retrieved dataset on this specific topic (LAG-3 + PD-1 combination for melanoma), holding at least three jurisdiction-distinct filings (SG, IL) with pending or inactive legal status. This signals a deliberate strategy to build a broad IP position around the LAG-3/PD-1 combination for first-line treatment of unresectable melanoma.
Approximately half of advanced patients fail to achieve durable benefit from either BRAF/MEK inhibitors or PD-1/CTLA-4 checkpoint blockade. Retrieved results consistently cite approximately 50% primary or acquired resistance to both checkpoint and BRAF-targeted therapy; every emerging modality (TIL, LAG-3, TAMs, epigenetic agents, CXCR4 blockade) is positioned as a resistance-circumvention strategy rather than a standalone replacement.
TAMs are described as a highly diverse and plastic cellular subset supporting melanoma growth, angiogenesis, and invasion. Monoclonal antibody strategies to redirect TAM polarization or deplete pro-tumor TAM populations are outlined as a complement to existing checkpoint immunotherapy. No clinical signal was identified in retrieved results for TAM-targeting approaches specifically in melanoma; evidence remains preclinical or biomarker-discovery stage.
VISTA (V-domain Immunoglobulin Suppressor of T cell Activation) is identified as a novel immune checkpoint of emerging interest. Retrieved data from the University of Medicine in Targu Mures describes it as potentially important in determining invasive potential and treatment response in melanoma, with limited published studies at time of writing. Signals suggest early-stage investigational interest.
Retrieved patents from Bristol-Myers Squibb explicitly integrate LAG-3 TIL expression, PD-L1 status, and BRAF mutation genotyping into patient selection. Academic evidence supports TIL cluster density, CAF gene expression panels, ctDNA, and miRNA signatures as additional response predictors. Biomarker stratification is becoming inseparable from therapy design in next-generation melanoma trials.
Still have questions about the melanoma pipeline? Let PatSnap Eureka answer them with live patent and literature data.
Ask PatSnap EurekaAccelerate Your Melanoma Pipeline Research with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search TIL, LAG-3, TAM, and TME patent landscapes in minutes—not weeks.
References
- Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches — University of Illinois at Chicago, 2021
- VISTA, PDL-L1, and BRAF—A Review of New and Old Markers in the Prognosis of Melanoma — University of Medicine "George Emil Palade" of Targu Mures, 2022
- Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070 — Newcastle University, 2013
- The Emerging Role of the Thrombin Receptor (PAR-1) in Melanoma Metastasis — Cancer Biology, 2011
- Adoptive Cell Therapy for Patients with Melanoma — Surgery Branch, National Cancer Institute, NIH, 2011
- Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option — The Netherlands Cancer Institute, 2018
- Combination therapy for melanoma — Bristol-Myers Squibb Company, 2021, SG [Patent]
- Combination therapy for melanoma — Bristol-Myers Squibb Company, 2022, IL [Patent]
- Combination therapy for melanoma — Bristol-Myers Squibb Company, 2021, IL [Patent]
- Overcoming melanoma resistance to immune checkpoint blockade therapy using nano-strategies — Nanjing University of Science and Technology, 2023
- Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies — King's College London, Guy's Hospital, 2022
- A Cancer Associated Fibroblasts-Related Six-Gene Panel for Anti-PD-1 Therapy in Melanoma — Chongqing Medical University, 2022
- Current status of intralesional agents in treatment of malignant melanoma — Cleveland Clinic Foundation, Taussig Cancer Institute, 2021
- The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling — University of Alabama at Birmingham, 2021
- Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma — Yale University School of Medicine, 2019
- Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas — University Hospital Cologne, 2021
- Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis — The Second People's Hospital of Dongying, 2021
- Combined targeted therapy and immunotherapy in melanoma — The University of Texas MD Anderson Cancer Center, 2019
- Beyond BRAF: where next for melanoma therapy? — Moffitt Cancer Center and Research Institute, 2014
- U.S. Food and Drug Administration (FDA) — T-VEC Approval Reference
- National Institutes of Health (NIH) — National Cancer Institute Nano-Delivery Research
- American Society of Clinical Oncology (ASCO) — Triple Combination Melanoma Strategies
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.